

How Do I Plan and Prepare for Redo TAVR?

Oskar Angerås, MD PhD

Sahlgrenska University Hospital, Gothenburg, Sweden



TRANSCATHETER
CARDIOVASCULAR
THERAPEUTICS®



SAHLGRENSKA AKADEMIN

Disclosure of Relevant Financial Relationships

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

Nature of Financial Relationship

Grant/Research Support

Consultant Fees/Honoraria

Individual Stock(s)/Stock Options

Ineligible Company



Abbott, Medtronic

Abbott, Medtronic, Meril, Novo Nordisk

Texray


Patient panorama

- Redo-TAVI is still relatively rare in Europe



Patient panorama

- Redo-TAVI is still relatively rare in Europe



- The valve "survives" the patient
 - Durability is most important when selecting index valve


Planing redo-TAVR

- Risks
 - Priorities
 1. Coronary occlusion – procedural risk!
 2. Coronary access – post-procedural risk
 3. Long-time durability – long term post-procedural risk
- Know the index valve
 - Commisures
 - Neo-skirt
 - Stent frame cells
 - Landmarks for positioning second valve

Index TAV Classification with Landmarks for Optimal Positioning & Sizing

	A Sapien XT / Sapien 3	B Myval	C Lotus	D Portico / Navitor	E CoreValve / Evolut	F ACURATE	G Allegra
Classification							
Frame Height	Short Frame			Tall Frame			
TAV Design	Intra-annular				Supra-annular		
Shape	Balloon-Expandable				Mechanical-expanding		
Same Shape for all sizes	Cylindrical				Cylindrical but complex		
	Yes				No	Yes	
Landmarks for Optimal Positioning & Sizing							
Top of Deflected Leaflets							
Nadir of Leaflets							
Important Fluoroscopic landmark							
Measurement levels for second TAV sizing	Inflow, mid (narrowest) and outflow	inflow, mid (narrowest) and outflow	Inflow, outflow, waist and bottom of the tuning fork	From node 0 to node 3	From node 1 to node 6	Bottom of the upper crown (waist) & node 1	Node 1 to Node 5
Compatible Second TAV							
Sapien 3	Compatible						
MyVal	Compatible						
Navitor	Compatible			Under Investigation			
Evolut	Compatible			Under Investigation	Compatible	Under Investigation	
ACURATE	Compatible		Incompatible			Compatible	Incompatible
Allegra	Compatible		Under Investigation			Compatible	

Important measurements



- Coronary risk plane = distance from **bottom of stent frame** to **bottom of coronaries**
- Neoskirt plane = height from **bottom of stent frame** to full predicted neo skirt height
- STJ plane = height from **bottom of stent frame** to ST-junction
- VTC = Valve to coronary distance
- VTSTJ = Valce to ST-junction distance (area?)

ECG gated cardiac CT



1. Coronary risk plane = distance from **bottom of stent frame** to **bottom of coronaries**
2. Neoskirt plane = height from **bottom of stent frame** to full predicted neo skirt height
3. STJ plane = height from **bottom of stent frame** to ST-junction
4. VTC = Valve to coronary distance
5. VTSTJ = Valce to ST-junction distance (area?)

ECG gated cardiac CT



1. Coronary risk plane = distance from **bottom of stent frame** to **bottom of coronaries**
2. Neoskirt plane = height from **bottom of stent frame** to **full predicted neo skirt height**
3. STJ plane = height from **bottom of stent frame** to **ST-junction**
4. VTC = Valve to coronary distance
5. VTSTJ = Valce to ST-junction distance (**area!**)


**Failed Evolut 26 mm in
73-year old woman with
coronary disease**



ID Type	Label	Value
1	Vessel Length Left Coronary Height	26,3 mm
2	Vessel Length Right Coronary Height	27,6 mm
3	Vessel Length Sinus of Valsalva Height	35,1 mm



**Failed Evolut 29 mm
in 76-year old
woman**




ID Type	Label	Value
1	Vessel Length Right Coronary Height	15,7 mm

**Failed Evolut 26 mm in 65 year old
male with previous Mitroflow 23
and left main stent**







ID Type	Label	Value
1	Vessel Length Left Coronary Height	17,4 mm



Navitor 25 mm



**Failed Evolut 26 mm in
73-year old woman with
coronary disease**



3mensio

*Failed Evolut 29 mm
in 76-year old
woman*

MyVal 24,5 mm with coronary protection



Surgery



- Risk of coronary occlusion
- High risk for additional future interventions – PCI and TAVR
- Postoperative
 - 10 days in respirator
 - 15 days in ICU
 - Etc etc

Take-home Message

- Durability of index valve important to avoid redo-TAVR
- Preprocedural planning is of great importance
- How to prioritize
 1. Avoid coronary occlusion
 2. Future access to coronaries
 3. Long-term durability